Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Down 2.6%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price was down 2.6% during mid-day trading on Friday . The stock traded as low as $5.70 and last traded at $5.71. Approximately 533,313 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 1,789,751 shares. The stock had previously closed at $5.86.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Down 4.3 %

The company has a debt-to-equity ratio of 0.19, a current ratio of 5.60 and a quick ratio of 5.05. The company has a market capitalization of $800.32 million, a price-to-earnings ratio of -13.67 and a beta of 1.44. The firm has a 50-day moving average price of $5.42 and a two-hundred day moving average price of $6.11.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.14. The company had revenue of $50.30 million during the quarter, compared to analysts’ expectations of $46.30 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. As a group, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AUPH. Compagnie Lombard Odier SCmA boosted its position in Aurinia Pharmaceuticals by 8.7% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 25,000 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 2,000 shares during the last quarter. HighMark Wealth Management LLC raised its position in Aurinia Pharmaceuticals by 3.0% during the first quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 2,197 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Aurinia Pharmaceuticals by 9.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,634 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 2,390 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Aurinia Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 2,873 shares during the period. Finally, Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth about $30,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.